OCGN
Ocugen, Inc.
There isn't enough reported data to score OCGN yet.
OCGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
OCGN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OCGN PE Valuation
OCGN has no meaningful PE right now: it lost money over the past year.
OCGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OCGN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OCGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.20 | +$0.01 |
| Q2 2026 | -$0.26 | -$0.07 |
| Q1 2026 | -$0.24 | -$0.06 |
| Q4 2025 | -$0.23 | -$0.05 |
| Q3 2025 | -$0.21 | -$0.04 |
| Q2 2025 | -$0.19 | -$0.01 |
| Q1 2025 | -$0.18 | +$0.06 |
| Q4 2024 | -$0.18 | +$0.08 |
OCGN is still losing money, but less than at its worst: $0.20 per share over the past year, against $0.38 at its worst in late 2022.
OCGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2M | +11% |
| Q2 2026 | $1.5M | +8.4% |
| Q1 2026 | $1.5M | +3.5% |
| Q3 2025 | $1.8M | +54% |
| Q2 2025 | $1.4M | +20% |
| Q1 2025 | $1.5M | +46% |
| Q4 2024 | $764K | -46% |
OCGN's revenue is down over the past year, though its latest quarter was up: $2M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -910% | +96 points |
| Q2 2026 | -1105% | -100 points |
| Q1 2026 | -1164% | -185 points |
| Q3 2025 | -1006% | +161 points |
| Q2 2025 | -1005% | +349 points |
| Q1 2025 | -979% | +226 points |
| Q4 2024 | -1812% | -994 points |
| Q3 2024 | -1167% | N/A |
OCGN's operating margin was −910% last quarter, up 95 points from the same quarter a year ago.
OCGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$2.9M |
| Q2 2026 | -$12.2M | -$1.4M |
| Q1 2026 | -$21.8M | -$2.4M |
| Q4 2025 | -$14M | -$3.6M |
| Q3 2025 | -$13M | -$1.2M |
| Q2 2025 | -$10.8M | -$349K |
| Q1 2025 | -$19.4M | -$6.4M |
| Q4 2024 | -$10.4M | +$3.6M |
OCGN has burned cash in almost every quarter: −$64M over the past year, against −$54M the year before.
OCGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +534K shares |
| 1 year | +8.6% | +26.9M shares |
| 3 years | +32% | +82.7M shares |
| 5 years | +71% | +140M shares |
| Available history | +545% | +287M shares |
OCGN has 339M diluted shares, up 8.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
OCGN Net Leverage
OCGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OCGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 17.9 | Oversold |
OCGN's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
OCGN PE vs Healthcare Sector
OCGN has no meaningful PE right now: it lost money over the past year.
OCGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.88 | 1.1% below |
| 20 week MA | $1.13 | 23% below |
| 50 week MA | $1.39 | 37% below |
| 100 week MA | $1.19 | 27% below |
| 200 week MA | $1.05 | 17% below |
OCGN is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
OCGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $1.76 | +340% |
| 2021 | $1.76 | $5.30 | +201% |
| 2022 | $5.30 | $1.21 | -77% |
| 2023 | $1.21 | $0.57 | -53% |
| 2024 | $0.57 | $0.85 | +49% |
| 2025 | $0.85 | $1.41 | +66% |
| 2026 YTD | $1.41 | $0.87 | -38% |
OCGN's yearly returns have swung widely, from +340% in 2020 to −77% in 2022. It's down 38% so far in 2026.